RPS10 Antibody

What is RPS10 and why is it important in cellular function?

RPS10 (ribosomal protein S10, also known as eS10) is a key component of the 40S ribosomal subunit with a calculated molecular weight of approximately 19 kDa. It plays a crucial role in ribosome assembly and protein synthesis mechanisms within cells. The protein is essential for proper ribosomal function, and its dysregulation has been linked to various pathological conditions including cancer, neurodegenerative disorders, and developmental abnormalities . RPS10 has particular significance in translational quality control pathways, where its ubiquitination serves as a regulatory mechanism. The evolutionary conservation of RPS10 across species including humans, mice, and rats underscores its fundamental importance in cellular machinery across mammalian systems.

What types of RPS10 antibodies are available for research applications?

Researchers have access to several types of RPS10 antibodies optimized for different experimental approaches. These include mouse monoclonal antibodies like the 67609-1-Ig, which shows high specificity with minimal cross-reactivity . Rabbit polyclonal antibodies such as CAB6056 provide an alternative option with potentially broader epitope recognition . The selection between monoclonal and polyclonal options depends largely on the specific application requirements and experimental design. Monoclonal antibodies offer consistent reproducibility across experiments with high specificity for a single epitope, while polyclonal antibodies may provide enhanced sensitivity by recognizing multiple epitopes on the RPS10 protein. Both antibody types have been validated across multiple applications including Western blot, immunohistochemistry, and immunofluorescence techniques.

How do I determine the appropriate RPS10 antibody for my specific experiment?

Selecting the optimal RPS10 antibody requires consideration of several experimental factors. First, identify which species you're studying, as RPS10 antibodies show different reactivity profiles - most commercial antibodies demonstrate reactivity with human, mouse, and rat samples . Second, determine your application requirements, as different antibodies are validated for specific techniques (Western blot, IHC-P, IF/ICC, ELISA). For instance, the mouse monoclonal 67609-1-Ig is recommended at dilutions of 1:1000-1:2000 for Western blot applications , while the rabbit polyclonal CAB6056 has recommended dilutions of 1:500-1:1000 for Western blot and 1:20-1:200 for IHC-P . Additionally, consider whether your experimental design requires detection of specific post-translational modifications of RPS10, such as ubiquitination or methylation, which might necessitate modification-specific antibodies. Testing the antibody on positive control samples (such as HepG2, Jurkat, K-562, HSC-T6, or NIH/3T3 cells) is advisable for validation before proceeding with critical experiments.

What are the validated applications for RPS10 antibodies and their optimal protocols?

RPS10 antibodies have been validated for multiple research applications with specific optimization guidelines for each technique. For Western blot applications, protocols typically involve dilutions between 1:500-1:2000 depending on the specific antibody . When performing immunoprecipitation assays to study RPS10 interactions or modifications, researchers should consider using FLAG-tagged systems that have demonstrated success in co-immunoprecipitation of RPS10 . For immunohistochemistry applications (IHC-P), dilutions between 1:20-1:200 are typically recommended . Immunofluorescence/immunocytochemistry (IF/ICC) applications generally use dilutions between 1:20-1:100 . It is important to note that optimal conditions may vary depending on sample type and preparation methods, so preliminary titration experiments are often necessary to determine the ideal antibody concentration for specific experimental systems. Researchers should also consider incorporating appropriate controls, including both positive controls (e.g., cell lines known to express RPS10) and negative controls to validate specificity.

How should I optimize Western blot conditions for detecting RPS10?

Optimizing Western blot conditions for RPS10 detection requires attention to several technical details. Based on RPS10's calculated molecular weight of 19 kDa, researchers should use appropriate percentage polyacrylamide gels (12-15%) that provide optimal resolution in this molecular weight range . For sample preparation, lysis buffers containing protease inhibitors are essential to prevent degradation of RPS10. When detecting ubiquitinated forms of RPS10, consider including deubiquitinase inhibitors in your lysis buffer to preserve these modifications. For primary antibody incubation, dilutions of 1:1000-1:2000 for monoclonal antibodies or 1:500-1:1000 for polyclonal antibodies are recommended as starting points, with overnight incubation at 4°C often yielding optimal results. Positive control samples from cell lines such as HepG2, Jurkat, K-562, HSC-T6, or NIH/3T3 cells can serve as validation references . When troubleshooting, consider that RPS10 may display altered migration patterns if post-translationally modified, particularly when ubiquitinated, potentially appearing as higher molecular weight bands above the expected 19 kDa mark. As observed in research studies, ubiquitinated RPS10 can appear as distinct bands at higher molecular weights, with doubly ubiquitinated forms showing characteristic migration patterns .

What controls should be included when studying RPS10 post-translational modifications?

When investigating RPS10 post-translational modifications, multiple controls are essential for reliable interpretation. For ubiquitination studies, comparing wild-type conditions with samples expressing Znf598 (the E3 ubiquitin ligase for RPS10) and samples with Znf598 knockout (MZznf598) provides a comprehensive control set . Similarly, site-directed mutagenesis of key lysine residues (particularly K139 and K140) can serve as negative controls, as these have been identified as ubiquitination sites . For methylation studies examining PRMT5-mediated methylation of RPS10 at Arg158 and Arg160, controls should include PRMT5 knockdown/knockout conditions and RPS10 mutants where these arginine residues are substituted . Additionally, treatment controls with proteasome inhibitors (such as MG132) can be valuable when studying the stability and turnover of modified RPS10 forms . For all modification studies, inclusion of appropriate molecular weight markers is critical, as modified forms of RPS10 will display characteristic shifts in apparent molecular weight - monoubiquitinated RPS10 appears approximately 8-10 kDa above the unmodified form, while diubiquitinated forms show even greater size shifts .

How is RPS10 involved in ribosome-associated quality control pathways?

RPS10 plays a critical role in ribosome-associated quality control (RQC) pathways through its site-specific ubiquitination. When ribosomes stall during translation, they can collide with trailing ribosomes to form structures called disomes. This collision event triggers the ubiquitination of RPS10/eS10 (along with RPS20/uS10) by the E3 ubiquitin ligase Znf598 . This post-translational modification serves as a molecular signal that initiates the RQC pathway, which subsequently dissociates stalled ribosomes into subunits and facilitates degradation of incomplete nascent polypeptides . Research has demonstrated that RPS10 ubiquitination not only contributes to the RQC pathway but also promotes endonucleolytic cleavage of mRNAs with stalled ribosomes – a process known as no-go decay (NGD) . Through these mechanisms, RPS10 ubiquitination helps maintain cellular proteostasis and protects the eukaryotic translation system against various translational issues. This function highlights the importance of RPS10 beyond its structural role in ribosomes, positioning it as a regulatory component in translation quality control systems. Detailed immunoblotting analysis of ribosome preparations has revealed that RPS10 can exist in both unmodified and ubiquitinated states, with the latter increasing under conditions that challenge translational fidelity .

What is the relationship between RPS10 methylation by PRMT5 and cellular functions?

The methylation of RPS10 by protein-arginine methyltransferase 5 (PRMT5) represents a significant post-translational modification with implications for ribosomal function and cellular regulation. Research has identified RPS10 as a novel substrate for PRMT5, which interacts with RPS10 and catalyzes its methylation specifically at arginine residues 158 and 160 . This methylation appears to contribute to regulatory mechanisms affecting ribosomal assembly, potentially serving as a fine-tuning mechanism for cell number and organ size control. PRMT5 is known to function as an oncoprotein in various cellular contexts, suggesting that its interaction with and modification of RPS10 may have implications for cancer biology and cellular proliferation control mechanisms. The methodology for studying this interaction typically involves co-immunoprecipitation assays with appropriate antibodies against both RPS10 and PRMT5, followed by mass spectrometry analysis to confirm methylation sites. Researchers investigating this relationship should consider using methylation-specific antibodies or techniques that can distinguish methylated from unmethylated forms of RPS10, such as specialized mass spectrometry approaches or antibodies that specifically recognize methylated arginine residues.

How do I design experiments to investigate RPS10's role in disease models?

Designing experiments to investigate RPS10's role in disease models requires a multi-faceted approach. First, expression profiling of RPS10 in relevant disease tissues compared to normal controls using techniques like Western blotting with RPS10 antibodies at recommended dilutions (1:500-1:2000) or immunohistochemistry can establish baseline differences. For functional studies, CRISPR/Cas9-mediated knockout or knockdown of RPS10 in cell models can reveal phenotypic consequences, though complete knockout may be lethal given RPS10's essential role in translation. Alternatively, targeting the enzymes that modify RPS10, such as Znf598 (for ubiquitination) or PRMT5 (for methylation) , may provide insights into the importance of these post-translational modifications in disease contexts. To study translation-related functions specifically, ribosome profiling experiments comparing wild-type and RPS10-mutant conditions (particularly mutations at ubiquitination sites K139/K140 or methylation sites R158/R160) can reveal impacts on translational efficiency and accuracy. For animal models, conditional knockout systems are preferable to avoid developmental lethality. Importantly, researchers should incorporate analysis of RPS10 post-translational modifications using specific antibodies or mass spectrometry approaches, as these modifications appear critical to RPS10's regulatory functions beyond its structural role in ribosomes .

What are common issues when using RPS10 antibodies and how can they be resolved?

Researchers working with RPS10 antibodies may encounter several common challenges. One frequent issue is weak or absent signal in Western blots despite appropriate sample preparation. This can be addressed by adjusting antibody concentration (starting with the recommended dilutions of 1:1000-1:2000 for monoclonal or 1:500-1:1000 for polyclonal antibodies ), extending incubation time, or using more sensitive detection methods. Another common problem is the detection of multiple bands, potentially indicating degradation, post-translational modifications, or non-specific binding. To address this, researchers should verify sample preparation protocols (ensuring complete protease inhibition), optimize blocking conditions to reduce non-specific binding, and consider that RPS10 can exist in modified forms showing higher molecular weights (particularly ubiquitinated forms) . For immunoprecipitation experiments, weak pull-down efficiency may occur. This can be improved by adjusting lysis conditions, antibody amounts, or incubation times. In immunohistochemistry applications, high background staining can be minimized by optimizing blocking conditions and antibody dilutions (starting with 1:20-1:200) . For all applications, verification using positive control samples from cell lines known to express RPS10 (such as HepG2, Jurkat, K-562, HSC-T6, or NIH/3T3) and negative controls (such as RPS10 knockdown samples) is essential for troubleshooting and validating results.

How can I differentiate between unmodified RPS10 and its post-translationally modified forms?

Differentiating between unmodified RPS10 and its post-translationally modified forms requires specialized techniques and careful experimental design. Western blot analysis serves as a primary method, where unmodified RPS10 appears at approximately 19 kDa , while ubiquitinated forms display characteristic shifts to higher molecular weights - monoubiquitinated RPS10 appears approximately 8-10 kDa larger, and diubiquitinated forms show even greater size increases . Using gradient gels (e.g., 4-15%) can improve resolution between these forms. For definitive identification of ubiquitinated RPS10, researchers can perform immunoprecipitation with RPS10 antibodies followed by immunoblotting with ubiquitin antibodies, or vice versa. Alternatively, mass spectrometry analysis of ribosome preparations can identify specific modification sites, as demonstrated by the detection of Rps10/eS10 peptides with di-glycine remnants at lysine 139, indicating ubiquitination . For studying methylated forms, similar approaches can be used, though methylation adds less mass than ubiquitination. Site-directed mutagenesis of key residues (K139/K140 for ubiquitination or R158/R160 for methylation ) can generate negative controls that help confirm the identity of modified bands. Additionally, treatments that enhance specific modifications, such as Znf598 overexpression to increase ubiquitination or proteasome inhibitors like MG132 to prevent degradation of ubiquitinated proteins , can be employed to facilitate detection and characterization of modified RPS10 forms.

What strategies should I employ when working with RPS10 antibodies in different cell types or tissues?

Adapting RPS10 antibody protocols for different cell types or tissues requires systematic optimization strategies. First, evaluate baseline RPS10 expression in your specific cellular models, as expression levels may vary significantly between different cell types or tissues. For cell lines with lower RPS10 expression, increasing protein loading amounts (50-100 μg total protein) or using more sensitive detection systems may be necessary. Sample preparation should be tailored to the specific tissue or cell type - for tissues with high protease activity (like pancreas or liver), additional protease inhibitors beyond standard cocktails may be beneficial. When working with primary tissues, fresh samples typically yield better results than fixed or archived materials. For challenging tissues, antigen retrieval methods in immunohistochemistry applications may need optimization beyond standard protocols. Antibody concentrations often require adjustment for different sample types - starting with the manufacturer's recommended dilutions (1:1000-1:2000 for Western blot with monoclonal antibodies or 1:500-1:1000 with polyclonal antibodies ) and performing titration experiments to determine optimal concentration for your specific sample type. When comparing RPS10 across tissues or cell types, housekeeping protein selection is critical - while GAPDH or β-tubulin are commonly used, for ribosomal protein studies, normalization to another ribosomal protein that remains constant across your experimental conditions may provide more accurate comparisons.

How are RPS10 antibodies used in studying translation-related diseases?

RPS10 antibodies have become instrumental in investigating various translation-related diseases, particularly ribosomopathies and cancer. In cancer research, RPS10 antibodies enable researchers to assess alterations in ribosomal composition and function that may contribute to dysregulated translation in malignant cells. Immunohistochemistry with RPS10 antibodies at dilutions of 1:20-1:200 on tissue microarrays allows for high-throughput screening of RPS10 expression patterns across different cancer types and stages. For studying ribosomopathies (genetic disorders caused by ribosomal protein mutations or deficiencies), Western blot analysis with RPS10 antibodies can reveal abnormal levels or post-translational modifications of RPS10 that may contribute to disease pathogenesis. Additionally, RPS10 antibodies facilitate the investigation of how therapeutic compounds targeting the translation machinery affect ribosomal composition and function. For instance, researchers can use immunofluorescence/immunocytochemistry with RPS10 antibodies (at dilutions of 1:20-1:100) to monitor changes in RPS10 localization in response to treatments. Furthermore, the role of RPS10 ubiquitination in quality control pathways makes RPS10 antibodies valuable for studying diseases associated with protein misfolding and aggregation, where these pathways may be compromised. In such studies, researchers should carefully select antibodies that can distinguish between modified and unmodified forms of RPS10 or combine standard RPS10 antibodies with specific techniques to detect post-translational modifications.

What new insights have been gained about RPS10's role through advanced antibody-based techniques?

Recent research utilizing advanced antibody-based techniques has revealed nuanced aspects of RPS10 function beyond its structural role in ribosomes. Proximity ligation assays using RPS10 antibodies have identified previously unknown interaction partners, expanding our understanding of RPS10's involvement in various cellular pathways. Mass spectrometry analysis following RPS10 immunoprecipitation has uncovered that site-specific ubiquitination at lysine 139 serves as a critical signal in ribosome-associated quality control pathways . This modification, mediated by the E3 ubiquitin ligase Znf598, triggers mechanisms that resolve ribosomal collisions occurring during translational stalling . Furthermore, ChIP-seq experiments with RPS10 antibodies have suggested potential extraribosomal functions, including possible roles in transcriptional regulation. Super-resolution microscopy combined with RPS10 immunofluorescence has provided insights into the spatial distribution of RPS10 within the cell under various stress conditions. Ribosome profiling experiments comparing wild-type conditions with those where RPS10 ubiquitination is prevented (either through Znf598 knockout or mutation of ubiquitination sites K139/K140) have revealed that this modification affects translation of specific mRNA subsets rather than global translation . Additionally, studies combining RPS10 antibodies with methylation-specific detection methods have shown that PRMT5-mediated methylation at arginine residues 158 and 160 represents another layer of RPS10 regulation with potential implications for ribosomal assembly and function .

How might RPS10 antibodies contribute to developing targeted therapeutics for ribosome-related disorders?

RPS10 antibodies offer significant potential for advancing therapeutic approaches for ribosome-related disorders through multiple research avenues. As diagnostic tools, these antibodies can help identify patient populations with abnormal RPS10 expression or modification patterns who might benefit from specific therapeutic interventions. For drug discovery efforts, high-throughput screening assays incorporating RPS10 antibodies (at dilutions optimized for the specific application, typically 1:500-1:2000 for detection methods ) can identify compounds that normalize aberrant RPS10 modifications or restore proper ribosomal function. The understanding of RPS10 ubiquitination in quality control pathways, enabled by specific antibody detection, may lead to therapies aimed at modulating these pathways in diseases characterized by translational stress, such as certain neurodegenerative disorders. For development of ribosomopathy treatments, RPS10 antibodies can serve as critical tools for evaluating how candidate therapeutics affect not only RPS10 levels but also its incorporation into functional ribosomes. In precision medicine approaches, immunohistochemistry with RPS10 antibodies (at dilutions of 1:20-1:200) might help stratify patients based on RPS10 status, potentially predicting response to translation-targeting therapies. Furthermore, RPS10 antibodies conjugated to therapeutic agents could theoretically provide targeted delivery to cells with aberrant ribosome composition, though such applications remain in early research stages. As therapeutic development progresses, these antibodies will continue to serve as essential tools for mechanism-of-action studies and target engagement validation.